BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 28287251)

  • 1. Cisplatin induced apoptosis of ovarian cancer A2780s cells by activation of ERK/p53/PUMA signals.
    Song H; Wei M; Liu W; Shen S; Li J; Wang L
    Histol Histopathol; 2018 Jan; 33(1):73-79. PubMed ID: 28287251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.
    Fraser M; Bai T; Tsang BK
    Int J Cancer; 2008 Feb; 122(3):534-46. PubMed ID: 17918180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Propofol induces apoptosis of non-small cell lung cancer cells via ERK1/2-dependent upregulation of PUMA.
    Xing SG; Zhang KJ; Qu JH; Ren YD; Luan Q
    Eur Rev Med Pharmacol Sci; 2018 Jul; 22(13):4341-4349. PubMed ID: 30024623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The p53 upregulated modulator of apoptosis (PUMA) chemosensitizes intrinsically resistant ovarian cancer cells to cisplatin by lowering the threshold set by Bcl-x(L) and Mcl-1.
    Yuan Z; Cao K; Lin C; Li L; Liu HY; Zhao XY; Liu L; Deng HX; Li J; Nie CL; Wei YQ
    Mol Med; 2011; 17(11-12):1262-74. PubMed ID: 21863213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Restoration of IRF1-dependent anticancer effects by MEK inhibition in human cancer cells.
    AbuSara N; Razavi S; Derwish L; Komatsu Y; Licursi M; Hirasawa K
    Cancer Lett; 2015 Feb; 357(2):575-81. PubMed ID: 25497010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P73 regulates cisplatin-induced apoptosis in ovarian cancer cells via a calcium/calpain-dependent mechanism.
    Al-Bahlani S; Fraser M; Wong AY; Sayan BS; Bergeron R; Melino G; Tsang BK
    Oncogene; 2011 Oct; 30(41):4219-30. PubMed ID: 21516125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pazopanib, a novel multi-kinase inhibitor, shows potent antitumor activity in colon cancer through PUMA-mediated apoptosis.
    Zhang L; Wang H; Li W; Zhong J; Yu R; Huang X; Wang H; Tan Z; Wang J; Zhang Y
    Oncotarget; 2017 Jan; 8(2):3289-3303. PubMed ID: 27924057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells.
    Fraser M; Leung BM; Yan X; Dan HC; Cheng JQ; Tsang BK
    Cancer Res; 2003 Nov; 63(21):7081-8. PubMed ID: 14612499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of LRRC8A protects human ovarian and alveolar carcinoma cells against Cisplatin-induced expression of p53, MDM2, p21Waf1/Cip1, and Caspase-9/-3 activation.
    Sørensen BH; Nielsen D; Thorsteinsdottir UA; Hoffmann EK; Lambert IH
    Am J Physiol Cell Physiol; 2016 Jun; 310(11):C857-73. PubMed ID: 26984736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ERK1/2 activation mediated by the nutlin‑3‑induced mitochondrial translocation of p53.
    Lee SY; Shin SJ; Kim HS
    Int J Oncol; 2013 Mar; 42(3):1027-35. PubMed ID: 23314357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents.
    Mujoo K; Watanabe M; Nakamura J; Khokhar AR; Siddik ZH
    J Cancer Res Clin Oncol; 2003 Dec; 129(12):709-18. PubMed ID: 14513366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tubeimoside I sensitizes cisplatin in cisplatin-resistant human ovarian cancer cells (A2780/DDP) through down-regulation of ERK and up-regulation of p38 signaling pathways.
    Liu HZ; Yu C; Yang Z; He JL; Chen WJ; Yin J; Li WM; Liu HT; Wang YX
    Mol Med Rep; 2011; 4(5):985-92. PubMed ID: 21687949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of ROS and subsequent DNA-damage response in PUMA-induced apoptosis of ovarian cancer cells.
    Yang J; Zhao X; Tang M; Li L; Lei Y; Cheng P; Guo W; Zheng Y; Wang W; Luo N; Peng Y; Tong A; Wei Y; Nie C; Yuan Z
    Oncotarget; 2017 Apr; 8(14):23492-23506. PubMed ID: 28423586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pro-survival effects by NF-κB, Akt and ERK(1/2) and anti-apoptosis actions by Six1 disrupt apoptotic functions of TRAIL-Dr4/5 pathway in ovarian cancer.
    Yang J; Li G; Zhang K
    Biomed Pharmacother; 2016 Dec; 84():1078-1087. PubMed ID: 27780136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin.
    Persons DL; Yazlovitskaya EM; Cui W; Pelling JC
    Clin Cancer Res; 1999 May; 5(5):1007-14. PubMed ID: 10353733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of TAp73 by platinum-based compounds to overcome drug resistance in p53 dysfunctional chronic lymphocytic leukemia.
    Tonino SH; Mulkens CE; van Laar J; Derks IA; Suo G; Croon-de Boer F; van Oers MH; Eldering E; Wang JY; Kater AP
    Leuk Lymphoma; 2015; 56(8):2439-47. PubMed ID: 25511680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JNK- and Akt-mediated Puma expression in the apoptosis of cisplatin-resistant ovarian cancer cells.
    Zhao Z; Wang J; Tang J; Liu X; Zhong Q; Wang F; Hu W; Yuan Z; Nie C; Wei Y
    Biochem J; 2012 Jun; 444(2):291-301. PubMed ID: 22394200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IRF-1 expression is induced by cisplatin in ovarian cancer cells and limits drug effectiveness.
    Pavan S; Olivero M; Corà D; Di Renzo MF
    Eur J Cancer; 2013 Mar; 49(4):964-73. PubMed ID: 23079474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The BH3-only protein, PUMA, is involved in oxaliplatin-induced apoptosis in colon cancer cells.
    Wang X; Li M; Wang J; Yeung CM; Zhang H; Kung HF; Jiang B; Lin MC
    Biochem Pharmacol; 2006 May; 71(11):1540-50. PubMed ID: 16595125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein.
    Abedini MR; Muller EJ; Bergeron R; Gray DA; Tsang BK
    Oncogene; 2010 Jan; 29(1):11-25. PubMed ID: 19802016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.